Precigen (PGEN) Other Non-Current Liabilities (2012 - 2026)
Precigen (PGEN) posted quarterly Other Non-Current Liabilities of $106000.0 for Q1 2026, down 99.87% year-over-year from $83.0 million in Q1 2025, and down 20.9% quarter-over-quarter from $134000.0 in Q4 2025.
Powered by 
Analysis
Precigen (PGEN) Other Non-Current Liabilities (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Other Non-Current Liabilities for 13 consecutive years, with $106000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 99.87% year-over-year to $106000.0; the TTM figure through Mar 2026 stood at $106000.0 (down 99.87% YoY), while the FY2025 annual figure was $134000.0, changed N/A from the prior year.
- Other Non-Current Liabilities retreated to $106000.0 in Q1 2026 per PGEN's latest filing, from $134000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $83.0 million in Q1 2025 and bottomed at $50000.0 in Q1 2022.
- Historically, Other Non-Current Liabilities has averaged $32.4 million across 3 years, with a median of $134000.0 in 2025.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities plunged 50.0% — and 2026, when it slumped 99.87%.
- Precigen's Other Non-Current Liabilities stood at $50000.0 in 2022, then soared by 168.0% to $134000.0 in 2025, then dropped by 20.9% to $106000.0 in 2026.
- Business Quant data shows PGEN's Other Non-Current Liabilities at $106000.0 in Q1 2026, $134000.0 in Q4 2025, and $78.6 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 77,000.00 |
| Mar 31, 2026 | 106,000.00 |
| Dec 31, 2025 | 134,000.00 |
| Sep 30, 2025 | 163,000.00 |
| Jun 30, 2025 | 78.56 Mn |
| Mar 31, 2025 | 83.02 Mn |
| Dec 31, 2024 | 50.54 Mn |
| Mar 31, 2022 | 50,000.00 |
| Dec 31, 2021 | 50,000.00 |
| Sep 30, 2021 | 50,000.00 |
| Jun 30, 2021 | 50,000.00 |
| Mar 31, 2021 | 100,000.00 |
| Dec 31, 2020 | 100,000.00 |
| Sep 30, 2020 | 100,000.00 |
| Jun 30, 2020 | 100,000.00 |
| Sep 30, 2019 | 221,000.00 |
| Jun 30, 2019 | 222,000.00 |
| Mar 31, 2019 | 662,000.00 |
| Dec 31, 2018 | 3.14 Mn |
| Sep 30, 2018 | 3.20 Mn |